Skip to main contentAI and Advanced
/
NATCOPHARM · NSEMarket ticker unavailable · configure an authorised index feed
NA
NSE · Equity shares · Biotechnology & Drugs-0.15 · -0.02%
Natco Pharma NATCOPHARM
NSE:INR 815.95
BSE:INR 912.85
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for NATCOPHARM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 816.1
Day rangeINR 801 — INR 828.75
52-week rangeINR 789 — INR 1,226.8
Volume4.93 L
Market cap16,350.04
P/E12.3
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)4,078.3
Net Income (INR Cr)1,418.5
Rev Growth (5 Year %)14.72
EPS Growth (5 Year %)26.8
P/E Ratio12.3
Book Value500.46
EPS79.2
Price/BV1.63Computed
Research path: Interpret Natco Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NATCOPHARMNatco Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 11,073.7 | 8,630.8 | 6,906.3 |
| Cash Equivalents | 1,550.9 | 53.9 | 6.3 |
| Other Liabilities Total | 67.3 | 70.2 | 74.9 |
| Long Term Debt | 100 | Not available | Not available |
| Common Stock Total | 35.8 | 35.8 | 35.8 |
| Other Current Assets Total | 381.9 | 324.7 | 390 |
| Total Assets | 11,073.7 | 8,630.8 | 6,906.3 |
| Current Portof LT Debt/Capital Leases | 3.3 | 1.7 | 2.7 |
| Total Equity | 9,221.1 | 7,607 | 5,853.1 |
| Long Term Investments | 2,610.9 | 309.4 | 120.9 |
| Retained Earnings(Accumulated Deficit) | 9,185.3 | 6,359.5 | 4,578.6 |
| Total Common Shares Outstanding | 17.91 | 17.91 | 17.91 |
| Tangible Book Valueper Share Common Eq | 500.46 | 409.85 | 316.01 |
| Goodwill Net | 63 | 57.4 | 56 |
| Total Liabilities | 1,852.6 | 1,023.8 | 1,053.2 |
| Total Debt | 713.9 | 279.4 | 371.2 |
| Short Term Investments | 1,320 | 2,369.9 | 1,320.8 |
| Cashand Short Term Investments | 2,870.9 | 2,489.9 | 1,391.2 |
| Total Receivables Net | 891 | 1,575.5 | 1,421.7 |
| Notes Payable/Short Term Debt | 606.4 | 273.1 | 363.2 |
| Deferred Income Tax | 0.2 | 0.2 | 0.2 |
| Accounts Receivable-Trade Net | 881.2 | 1,347 | 1,255.3 |
| Property/Plant/Equipment Total-Net | 2,839.1 | 2,657.3 | 2,435 |
| Minority Interest | 0 | 5.3 | Not available |
| Total Current Liabilities | 1,680.9 | 943.5 | 972.8 |
| Total Inventory | 908.5 | 849.4 | 791.7 |
| Accounts Payable | 409.3 | 274.9 | 235.5 |
| Other Currentliabilities Total | 661.9 | 328.8 | 313.9 |
| Total Long Term Debt | 104.2 | 4.6 | 5.3 |
| Intangibles Net | 194.3 | 208.7 | 137.1 |
| Other Long Term Assets Total | 302.5 | 68.9 | 37.2 |
| Note Receivable-Long Term | 11.6 | 59.1 | 96.6 |
| Total Current Assets | 5,052.3 | 5,270 | 4,023.5 |
| Capital Lease Obligations | 4.2 | 4.6 | 5.3 |
| Accumulated Depreciation Total | Not available | -1,249.5 | -1,063.8 |
| Accrued Expenses | Not available | 65 | 57.5 |
| Other Equity Total | Not available | 9.8 | 36.8 |
| Prepaid Expenses | Not available | 30.5 | 28.9 |
| Additional Paid-In Capital | Not available | 1,201.9 | 1,201.9 |
| Cash | Not available | 66.1 | 64.1 |
| Property/Plant/Equipment Total-Gross | Not available | 3,681.4 | 3,361.5 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.44
Price to Sale Ratio4.01
Growth
Debt 5Yr CAGR %21.68
Margins
Operating Margin 12m30.16
Operating Margin 5y Avg32.96
Net Profit Margin 12m33.64
Net Profit Margin 5y32.22
Yield
Dividend Yield %0.54
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.47
Analyst consensus
ConsensusHold
Consensus score2.89
Analyst opinions9
Strong Sell count1
Sell count2
Hold count3
Buy count1
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 49.42%
- FII
- 16.99%
- MF
- 1.92%
- Other
- 31.67%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
FDA Grants Tentative Approval to Generic Olaparib Tablets - Oncology Nursing NewsMarket news · 20 Jul 2026, 9:34 pm
FDA Grants Tentative Approval to Generic Olaparib Tablets Oncology Nursing News
Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day - The HinduMarket news · 20 Jul 2026, 8:37 pm
Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day The Hindu
Alembic, NATCO Receive USFDA Tentative Approval for Generic Cancer Drug Olaparib - Medical DialoguesMarket news · 20 Jul 2026, 8:33 pm
Alembic, NATCO Receive USFDA Tentative Approval for Generic Cancer Drug Olaparib Medical Dialogues
NATCO Pharma rallies after USFDA grants tentative approval for Olaparib tablets - Business StandardMarket news · 20 Jul 2026, 4:51 pm
NATCO Pharma rallies after USFDA grants tentative approval for Olaparib tablets Business Standard
Natco Pharma Shares Gain After US FDA Tentative Approval for Generic Cancer Drug - NDTV ProfitMarket news · 20 Jul 2026, 10:25 am
Natco Pharma Shares Gain After US FDA Tentative Approval for Generic Cancer Drug NDTV Profit
Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets - The Economic TimesMarket news · 20 Jul 2026, 10:05 am
Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets The Economic Times
Corporate actions
Events
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsInter alia, to consider among other things, the Scheme of Arrangement for the demerger of Agrochemicals Division on a going concern basis into its WoS i.e., Natco Crop Health Sciences Limited.
- dividendRs.1.5000 per share(75%)Third Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- dividendRs.1.5000 per share(75%)Second Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Natco Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- NATCOPHARM
- BSE Code
- 524816
Questions
Stock FAQ
What is the symbol and ISIN of Natco Pharma?
Natco Pharma has the symbol NATCOPHARM and ISIN - INE987B01026.
What is the current price of Natco Pharma?
Natco Pharma is currently trading at INR 815.95.
What are the year high and year low of Natco Pharma?
Natco Pharma has a year high of INR 1,226.80 and a year low of INR 789.00.
What is the market capitalization of Natco Pharma?
Natco Pharma has a market capitalization of INR 16,350.04 crore.
What is the P/E ratio of Natco Pharma?
Natco Pharma has a P/E ratio of 12.30.
What is the dividend yield of Natco Pharma?
Natco Pharma has a dividend yield of 0.54%.
How is the financial performance of Natco Pharma based on revenue, net income, and EPS?
Natco Pharma has revenue of INR 4,078.30 crore, net income of INR 1,418.50 crore, and EPS of INR 79.20.
What is the book value of Natco Pharma?
Natco Pharma has a book value of INR 500.46.
What is the debt-to-equity ratio of Natco Pharma?
Natco Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Natco Pharma?
Natco Pharma has a price-to-book ratio of 1.63 and a price-to-sales ratio of 4.01.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.